ES2074946B1 - Nuevos compuestos derivados de la 1,2-etanodiamina-n,n,n',n'-tetrasustituida. - Google Patents

Nuevos compuestos derivados de la 1,2-etanodiamina-n,n,n',n'-tetrasustituida.

Info

Publication number
ES2074946B1
ES2074946B1 ES09301616A ES9301616A ES2074946B1 ES 2074946 B1 ES2074946 B1 ES 2074946B1 ES 09301616 A ES09301616 A ES 09301616A ES 9301616 A ES9301616 A ES 9301616A ES 2074946 B1 ES2074946 B1 ES 2074946B1
Authority
ES
Spain
Prior art keywords
pct
substituted
ethanodiamine
tetras
methylen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES09301616A
Other languages
English (en)
Other versions
ES2074946A1 (es
Inventor
Ambros Rafael Foguet
Ribera Santiago Gubert
Hernandez Jose A Ortiz
Munoz Aurelio Sacristan
Barenys Josep M Castello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferrer Internacional SA
Original Assignee
Ferrer Internacional SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrer Internacional SA filed Critical Ferrer Internacional SA
Priority to ES09301616A priority Critical patent/ES2074946B1/es
Priority to TW083103577A priority patent/TW262460B/zh
Priority to MX9403011A priority patent/MX9403011A/es
Priority to ZA943035A priority patent/ZA943035B/xx
Priority to PH48288A priority patent/PH30969A/en
Priority to DK94924260.6T priority patent/DK0660819T3/da
Priority to JP7504929A priority patent/JPH08503962A/ja
Priority to NZ271076A priority patent/NZ271076A/en
Priority to CA002144758A priority patent/CA2144758A1/en
Priority to DE69406406T priority patent/DE69406406T2/de
Priority to US08/392,987 priority patent/US5561135A/en
Priority to AT94924260T priority patent/ATE159511T1/de
Priority to AU74590/94A priority patent/AU670716B2/en
Priority to KR1019950701049A priority patent/KR950703515A/ko
Priority to PCT/EP1994/002363 priority patent/WO1995003270A1/en
Priority to EP94924260A priority patent/EP0660819B1/en
Priority to NO950974A priority patent/NO950974L/no
Priority to FI951277A priority patent/FI951277A/fi
Publication of ES2074946A1 publication Critical patent/ES2074946A1/es
Application granted granted Critical
Publication of ES2074946B1 publication Critical patent/ES2074946B1/es
Priority to GR980400111T priority patent/GR3025941T3/el
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/30—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/04—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated
    • C07C225/06—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and acyclic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

NUEVOS COMPUESTOS DERIVADOS DE LA 1,2-ETANODIAMINA-N,N,N",N''-TETRASUSTITUIDA. CONSISTE EN LOS NUEVOS COMPUESTOS DERIVADOS DE LA 1,2-ETANODIAMINA-N,N,N",N''-TETRASUSTITUIDA, DE FORMULA GENERAL (I): *FIG* DONDE "X" ES UN GRUPO CARBONILO (CO), HIDROXIMETILEN (CHOH) O P-FLUOROFENIL-METILEN (P-F-C6H4-CH) Y "R" ES UN RESTO BENCILO OPCIONALMENTE SUSTITUIDO EN P- POR UN HALOGENO O BIEN ES UN RESTO 2PIRIMIDINIL, A CONDICION DE QUE SIMULTANEAMENTE "X" NO SEA P-FLUOROFENIL-METILEN (P-F-C6H4-CH) Y "R" NO SEA UN RESTO BENCILO NO SUSTITUIDO, ASI COMO SUS SALES DE ADICION FARMACEUTICAMENTE ACEPTABLES. ESTOS COMPUESTOS SON DE USO POTENCIAL PARA TRATAR ENFERMEDADES DEL SISTEMA NERVIOSO SOMETIDAS A CONTROL DE LOS RECEPTORES SI.
ES09301616A 1993-07-19 1993-07-19 Nuevos compuestos derivados de la 1,2-etanodiamina-n,n,n',n'-tetrasustituida. Expired - Fee Related ES2074946B1 (es)

Priority Applications (19)

Application Number Priority Date Filing Date Title
ES09301616A ES2074946B1 (es) 1993-07-19 1993-07-19 Nuevos compuestos derivados de la 1,2-etanodiamina-n,n,n',n'-tetrasustituida.
TW083103577A TW262460B (es) 1993-07-19 1994-04-22
MX9403011A MX9403011A (es) 1993-07-19 1994-04-26 Nuevos compuestos derivados de la1,2-etanodiamina-n,n,n',n'-tetrasustituida.
ZA943035A ZA943035B (en) 1993-07-19 1994-05-03 N,N,N',N'-tetrasubstituted-1,2-ethanediamine derivative compounds
PH48288A PH30969A (en) 1993-07-19 1994-05-16 New N,N,N',N' tetrasubstituted-1,2-ethanediamine compounds.
PCT/EP1994/002363 WO1995003270A1 (en) 1993-07-19 1994-07-18 New n,n,n',n'-tetrasubstituted-1,2-ethanediamine derivative compounds
NZ271076A NZ271076A (en) 1993-07-19 1994-07-18 N-methyl-n-benzyl(or pyrimidinyl)-n'-methyl-n'-(substituted propyl)ethane-1,2-diamine derivatives and pharmaceutical compositions
CA002144758A CA2144758A1 (en) 1993-07-19 1994-07-18 New n,n,n',n'-tetrasubstituted-1,2-ethanediamine derivative compounds
DE69406406T DE69406406T2 (de) 1993-07-19 1994-07-18 Derivate von n,n,n',n'-tetrasubstituierten 1,2-ethylendiamin-verbindungen
US08/392,987 US5561135A (en) 1993-07-19 1994-07-18 N,N,N',N'-tetrasubstituted-1,2-ethanediamine derivative compounds
DK94924260.6T DK0660819T3 (da) 1993-07-19 1994-07-18 Nye N,N,N,N-tetrasubstituerede 1,2-ethandiaminderivatforbindelser
AU74590/94A AU670716B2 (en) 1993-07-19 1994-07-18 New N,N,N',N'-tetrasubstituted-1,2-ethanediamine derivative compounds
KR1019950701049A KR950703515A (ko) 1993-07-19 1994-07-18 신규 n,n,n',n'-2치환-1,2-에탄디아민 유도체 화합물(new n,n,n',n'-tetrasubstituted-1,2-ethanediamine derivative compounds)
JP7504929A JPH08503962A (ja) 1993-07-19 1994-07-18 新規ｎ，ｎ，ｎ’，ｎ’−テトラ置換−１，２−エタンジアミン誘導体化合物
EP94924260A EP0660819B1 (en) 1993-07-19 1994-07-18 New n,n,n',n'-tetrasubstituted-1,2-ethanediamine derivative compounds
AT94924260T ATE159511T1 (de) 1993-07-19 1994-07-18 Derivate von n,n,n',n'-tetrasubstituierten 1,2- ethylendiamin-verbindungen
NO950974A NO950974L (no) 1993-07-19 1995-03-14 Nye N,N,N',N'-tetrasubstituert-1,2-etandiaminderivatforbindelser
FI951277A FI951277A (fi) 1993-07-19 1995-03-17 Uudet N,N,N',N'-tetrasubstituoituneet 1,2-etaanidiamiinijohdannaisyhdisteet
GR980400111T GR3025941T3 (en) 1993-07-19 1998-01-16 New n,n,n',n'-tetrasubstituted-1,2-ethanediamine derivative compounds.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES09301616A ES2074946B1 (es) 1993-07-19 1993-07-19 Nuevos compuestos derivados de la 1,2-etanodiamina-n,n,n',n'-tetrasustituida.

Publications (2)

Publication Number Publication Date
ES2074946A1 ES2074946A1 (es) 1995-09-16
ES2074946B1 true ES2074946B1 (es) 1996-06-16

Family

ID=8282595

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09301616A Expired - Fee Related ES2074946B1 (es) 1993-07-19 1993-07-19 Nuevos compuestos derivados de la 1,2-etanodiamina-n,n,n',n'-tetrasustituida.

Country Status (19)

Country Link
US (1) US5561135A (es)
EP (1) EP0660819B1 (es)
JP (1) JPH08503962A (es)
KR (1) KR950703515A (es)
AT (1) ATE159511T1 (es)
AU (1) AU670716B2 (es)
CA (1) CA2144758A1 (es)
DE (1) DE69406406T2 (es)
DK (1) DK0660819T3 (es)
ES (1) ES2074946B1 (es)
FI (1) FI951277A (es)
GR (1) GR3025941T3 (es)
MX (1) MX9403011A (es)
NO (1) NO950974L (es)
NZ (1) NZ271076A (es)
PH (1) PH30969A (es)
TW (1) TW262460B (es)
WO (1) WO1995003270A1 (es)
ZA (1) ZA943035B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE757408A (fr) * 1969-10-13 1971-04-13 Thomae Gmbh Dr K Nouveaux butanols tertiaires a constituants basiques
FR2279383A1 (fr) * 1974-04-25 1976-02-20 Synthelabo Nouveaux derives tetrasubstitues des alcoylene-diamines, leurs sels, leur preparation et les medicaments qui en contiennent
US4605655A (en) * 1984-03-06 1986-08-12 Bristol-Myers Company Antipsychotic 1-fluorophenylbutyl-4-(2-pyrimidinyl)piperazine derivatives
US4588728A (en) * 1985-03-27 1986-05-13 Burroughs Wellcome Co. Treatment of drug induced psychosis
US4709094A (en) * 1986-07-10 1987-11-24 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Sigma brain receptor ligands and their use
US4929734A (en) * 1987-03-31 1990-05-29 Warner-Lambert Company Tetrahydropyridine oxime compounds
IT1205124B (it) * 1987-06-05 1989-03-15 Simens Soteta Italiana Medicin Composto attivo nella terapia carciovascolare
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
US5109002A (en) * 1989-09-08 1992-04-28 Du Pont Merck Pharmaceutical Company Antipsychotic 1-cycloalkylpiperidines
US5149817A (en) * 1990-03-05 1992-09-22 Shionogi & Co., Ltd. Teirahydropyridine derivatives
US5116995A (en) * 1990-05-25 1992-05-26 Taisho Pharmaceutical Co., Ltd. Carbazole compounds
JP2935541B2 (ja) * 1990-06-28 1999-08-16 サントリー株式会社 縮合複素環化合物
US5086054A (en) * 1990-07-31 1992-02-04 Sri International Novel arylcycloalkanepolyalkylamines
DE4032767A1 (de) * 1990-10-16 1992-04-30 Basf Ag Phenylpiperidinoylamine und diese enthaltende arzneimittel
EP0491243B1 (de) * 1990-12-19 1996-05-15 Kali-Chemie Pharma GmbH Alkylaminoalkylamin- und -äther- Verbindungen sowie Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5162341A (en) * 1991-02-22 1992-11-10 Du Pont Merck Pharmaceutical Company Use of sigma receptor antagonists for treatment of amphetamine abuse
FR2675799B1 (fr) * 1991-04-24 1993-12-24 Synthelabo Derives de 2-aminopyrimidine-4-carboxamide, leur preparation et leur application en therapeutique.

Also Published As

Publication number Publication date
US5561135A (en) 1996-10-01
FI951277A0 (fi) 1995-03-17
DK0660819T3 (da) 1998-01-12
PH30969A (en) 1997-12-23
CA2144758A1 (en) 1995-02-02
NO950974D0 (no) 1995-03-14
NZ271076A (en) 1996-03-26
ZA943035B (en) 1995-05-02
AU670716B2 (en) 1996-07-25
WO1995003270A1 (en) 1995-02-02
FI951277A (fi) 1995-03-17
AU7459094A (en) 1995-02-20
TW262460B (es) 1995-11-11
ES2074946A1 (es) 1995-09-16
EP0660819B1 (en) 1997-10-22
GR3025941T3 (en) 1998-04-30
EP0660819A1 (en) 1995-07-05
DE69406406D1 (de) 1997-11-27
MX9403011A (es) 1995-01-31
KR950703515A (ko) 1995-09-20
JPH08503962A (ja) 1996-04-30
NO950974L (no) 1995-03-14
DE69406406T2 (de) 1998-05-20
ATE159511T1 (de) 1997-11-15

Similar Documents

Publication Publication Date Title
PL313821A1 (en) Analogues of distamycin a as anticarcinogenic and antiviral agents
LU91751I2 (fr) Asenapin et ses dérivés pharmaceutiquement acceptables (SYCREST®)
BG103740A (en) Phytostyrene composition for the prevention of the alzheimer's disease
FR2714378B1 (fr) Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
DE69705300T2 (de) Cyclopropylalkansäurederivate
DK0907639T3 (da) Polymorfe forbindelser
EP0938317A4 (en) COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION
GR3033528T3 (en) Novel piperidine derivatives with paf antagonist activity
FI972434A (fi) Lamotrigiiniä sisältävä farmaseuttinen koostumus
ES2074946B1 (es) Nuevos compuestos derivados de la 1,2-etanodiamina-n,n,n',n'-tetrasustituida.
DK0804186T3 (da) Indolditerpenalkaloidforbindelser
UY23362A1 (es) Procedimiento para la preparacion de derivado de triciclo de la piridona
ES2087567T3 (es) Derivados antibioticos de 7'-amino-naftazarina.
SE9404438D0 (sv) New process
SG42910A1 (en) Benzopyrans
MY133957A (en) "compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor"

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20010301